Merz 10-month market ban for underhand tactics in Botox 'biosimilar' case
This article was originally published in Scrip
Executive Summary
Allergan won a permanent injunction to stop Merz Pharmaceuticals and Merz Aesthetics from selling their product Xeomin (botulinum toxin type A), a direct competitor for Allergan's wrinkle-reducing biologic Botox, in the US facial aesthetics market for the next 10 months.